Method for increasing intradermal retention amount of polypeptide in cosmetic and anti-aging cosmetic

Abstract

The invention relates to the field of cosmetics, in particular to a method for increasing the intradermal retention amount of polypeptide in cosmetics and anti-aging cosmetics. The invention provides a method for increasing the intradermal retention amount of polypeptide in cosmetics. The method comprises the following steps: mixing polypeptide with water to prepare a water-phase mixture; mixing phospholipid, grease and an antioxidant to obtain an oil-phase mixture; and dropwise adding the water-phase mixture into the oil-phase mixture to form a viscous reverse micelle structure. According to the technical scheme, the polypeptide and water are mixed to prepare the water-phase mixture, the water-phase mixture is dropwise added into the oil-phase mixture prepared by mixing the phospholipid, the grease and the antioxidant, and a viscous reverse micelle structure is formed. The viscous reverse micelle structure can be used as a carrier of polypeptide, and water-soluble polypeptide is carried below a natural lipid barrier formed by a cuticle; meanwhile, the viscous reverse micelle structure can improve the retention volume of the polypeptide in the skin; therefore, the real exertion of the anti-aging effect of the anti-aging cosmetics in the prior art can be effectively improved.

Description

Technical Field

[0001] The present application relates to the field of cosmetics, and in particular, to a method for increasing the intradermal retention of polypeptides in cosmetics and anti-aging cosmetics. Background Art

[0002] As we age and are attacked by the external environment, our skin ages. Consumers often prefer to use cosmetics with anti-aging functions to fight against premature skin aging, but in fact, cosmetics work through the functional ingredients they contain.

[0003] However, most of the effective anti-aging ingredients on the market find it difficult to penetrate the natural lipid barrier formed by the stratum corneum. These anti-aging ingredients can only better exert their effects by penetrating into the epidermis or dermis and accumulating in this skin layer.

[0004] For example, peptides have excellent anti-aging effects, but it is difficult for them to penetrate the natural lipid barrier formed by the stratum corneum, and their retention in the skin is limited, resulting in very limited anti-aging effects.

[0005] Known prior art, such as Chinese patent CN110339081B, usually uses oil-soluble surfactants as solubilizers to dissolve the polypeptide in oily solvents and increase its intradermal retention; however, this method needs to introduce oil-soluble surfactants, which can easily damage the skin and has low biosafety. Summary of the invention

[0006] The purpose of the embodiments of the present application is to provide a method for increasing the intradermal retention of polypeptides in cosmetics and anti-aging cosmetics.

[0007] In a first aspect, the present application provides a method for increasing the intradermal retention of a polypeptide in a cosmetic, comprising:

[0008] mixing the polypeptide with water to prepare an aqueous phase mixture;

[0009] The phospholipids, oils and antioxidants are mixed to prepare an oil phase mixture;

[0010] The aqueous phase mixture is added dropwise to the oil phase mixture to form a viscous reverse micelle structure.

[0011] In the above technical solution, the water phase mixture obtained by mixing the polypeptide with water is added dropwise to the oil phase mixture obtained by mixing phospholipids, oils and antioxidants, forming a viscous reverse micelle structure. This viscous reverse micelle structure can be used as a carrier of the polypeptide to carry the water-soluble polypeptide below the natural lipid barrier formed by the stratum corneum; at the same time, this viscous reverse micelle structure can increase the retention of the polypeptide in the skin; thereby effectively improving the anti-aging effect of the anti-aging cosmetics in the prior art.

[0012] In other embodiments of the present application, the above-mentioned step of mixing the polypeptide with water to prepare an aqueous phase mixture comprises:

[0013] In the aqueous phase mixture, the polypeptide and water are mixed in the ratio of (0.01% to 70%): (30% to 99.99%) by mass percentage.

[0014] In other embodiments of the present application, phospholipids, oils and antioxidants are mixed to prepare an oil phase mixture, including:

[0015] In terms of mass percentage, the phospholipids, oils and antioxidants are mixed in the ratio of (20% to 50%): (45% to 78%): (1.0% to 2.0%).

[0016] In other embodiments of the present application, the aqueous phase mixture is added dropwise to the oil phase mixture, comprising:

[0017] Add the homogeneous aqueous phase mixture dropwise into the oil phase mixture with stirring.

[0018] In other embodiments of the present application, the aqueous phase mixture is added dropwise to the oil phase mixture, comprising:

[0019] In terms of mass percentage, 1%-3% of the water phase mixture is added dropwise into 97%-99% of the oil phase mixture and stirred.

[0020] In other embodiments of the present application, the oil includes at least one of isopropyl palmitate, isopropyl myristate or isopropyl laurate.

[0021] In other embodiments of the present application, the antioxidant includes: tocopherol acetate.

[0022] In other embodiments of the present application, the polypeptide includes at least one of conopeptide, snake venom peptide or acetyl hexapeptide-8.

[0023] In other embodiments of the present application, the phospholipid includes lecithin, and the purity of the lecithin is 90% to 100%.

[0024] In a second aspect, the present application provides an anti-aging cosmetic, the anti-aging cosmetic comprising a polypeptide raw material;

[0025] The polypeptide raw material forms a viscous reverse micelle structure.

[0026] In other embodiments of the present application, the polypeptide raw material includes, by mass percentage: 45%-78% oil; 20%-50% phospholipids; 1.0%-2.0% antioxidant; 1.0%-3% water; and 0.0001%-1.0% polypeptide.

[0027] In other embodiments of the present application, the oil includes at least one of isopropyl palmitate, isopropyl myristate or isopropyl laurate.

[0028] In other embodiments of the present application, the antioxidant includes: tocopherol acetate.

[0029] In other embodiments of the present application, the polypeptide includes at least one of conopeptide, snake venom peptide or acetyl hexapeptide-8.

[0030] In other embodiments of the present application, the phospholipid includes lecithin, and the purity of the lecithin is 90% to 100%. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present application and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0032] Figure 1 This is a transmission electron microscopy image of the reverse micelle carrier carrying conopeptide prepared in Example 2 of the present application;

[0033] Figure 2 This is a transmission electron micrograph of the reverse micelle carrier prepared in Example 7 of the present application carrying a snake venom peptide;

[0034] Figure 3 This is a transmission electron micrograph of the reverse micelle carrier prepared in Example 12 of the present application carrying acetyl hexapeptide-8. DETAILED DESCRIPTION

[0035] In order to make the purpose, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions in the embodiments of the present application will be clearly and completely described below. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments.

[0036] Therefore, the following detailed description of the embodiments of the present application is not intended to limit the scope of the present application for protection, but merely represents selected embodiments of the present application. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present application.

[0037] Through research, it was found that phospholipids can form a reverse micelle structure to encapsulate water-soluble active substances and serve as a carrier for water-soluble active substances, thereby enhancing the stability of water-soluble active substances. Further research found that this reverse micelle structure can also carry peptides and increase the retention of peptides in the skin.

[0038] The present application provides a method for increasing the intradermal retention of a polypeptide in a cosmetic, comprising:

[0039] mixing the polypeptide with water to prepare an aqueous phase mixture;

[0040] The phospholipids, oils and antioxidants are mixed to prepare an oil phase mixture;

[0041] The aqueous phase mixture is added dropwise to the oil phase mixture to form a viscous reverse micelle structure.

[0042] In the above technical solution, the water phase mixture obtained by mixing the polypeptide with water is added dropwise to the oil phase mixture obtained by mixing the phospholipid with oil, thereby forming a viscous reverse micelle structure. This viscous reverse micelle structure can be used as a carrier of the polypeptide, carrying the water-soluble polypeptide below the natural lipid barrier formed by the stratum corneum; at the same time, this viscous reverse micelle structure can increase the retention of the polypeptide in the skin; thereby effectively improving the anti-aging effect of the anti-aging cosmetics in the prior art.

[0043] Further optionally, in some embodiments of the present application, the viscosity of the above-mentioned viscous reverse micelle structure is 25000 Pa·s-35000 Pa·s.

[0044] In some embodiments of the present application, the test method for the viscosity of the above-mentioned viscous reverse micelle structure is:

[0045] According to the estimated sample viscosity, select an appropriate rotor and install it on the rotating shaft of the rotational viscometer. Connect the rotor and the instrument drive system to ensure that it is tight and firm without shaking. Carefully pour the sample that has reached a constant temperature into the measuring cylinder slowly until the sample is immersed in the rotor scale position to avoid bubbles from mixing in. If there are bubbles, let it stand for a while until the bubbles escape or use a fine needle to gently prick the surface bubbles. Turn on the viscometer, set the speed, wait for the reading to stabilize, record the displayed viscosity value, and repeat the measurement 3 times.

[0046] Illustratively, in some embodiments of the present application, the viscosity of the viscous reverse micelle structure is 25000Pa·s, 26000Pa·s, 27000Pa·s, 28000Pa·s, 29000Pa·s, 30000Pa·s, 31000Pa·s, 32000Pa·s, 33000Pa·s, 34000Pa·s, 35000Pa·s or a range between any two of the foregoing values.

[0047] Further, in some embodiments of the present application, the polypeptide is mixed with water to prepare an aqueous phase mixture, comprising:

[0048] In terms of mass percentage, the polypeptide and water are mixed according to (0.01%-70%): (30%-99.99%).

[0049] Illustratively, in some embodiments of the present application, the above-mentioned mixing of the polypeptide with water to prepare an aqueous phase mixture comprises:

[0050] In the aqueous phase mixture, the polypeptide and water are mixed in a ratio of 0.01:99.99, 1:99, 5:95, 10:90, 15:85, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30 or a range between any two of the foregoing values, by mass percentage.

[0051] In the above technical solution, the polypeptide and water are mixed according to (0.01%-70%): (30%-99.99%) by mass percentage; this is conducive to obtaining a viscous reverse micelle structure with moderate viscosity, which is conducive to increasing the retention of the polypeptide in the skin.

[0052] Further, in some embodiments of the present application, phospholipids, oils and antioxidants are mixed to prepare an oil phase mixture, comprising:

[0053] In terms of mass percentage, the phospholipids, oils and antioxidants are mixed in the ratio of (20% to 50%): (45% to 78%): (1.0% to 2.0%).

[0054] For example, in some embodiments of the present application, phospholipids and oils are mixed to prepare an oil phase mixture, comprising:

[0055] In terms of mass percentage, the phospholipids and oils are mixed according to 20%:45%:1.0%; 21%:49%:1.1%; 22%:50%:1.2%; 25%:55%:1.3%; 28%:58%:1.4%; 30%:60%:1.5%; 32%:62%:1.6%; 35%:65%:1.7%; 38%:69%:1.8%; 40%:70%:1.9%; 45%:75%:2.0%; 48.5%:78%:1.0% or in a range between any two of the aforementioned values.

[0056] In the above technical solution, the phospholipids, oils and antioxidants are mixed in the ratio of (20% to 50%): (45%-78%): (1.0%-2.0%) by mass percentage; this is beneficial for obtaining a viscous reverse micelle structure with moderate viscosity, which is beneficial for increasing the retention of the polypeptide in the skin.

[0057] Further, in some embodiments of the present application, the aqueous phase mixture is added dropwise to the oil phase mixture, comprising:

[0058] Add the homogeneous aqueous phase mixture dropwise into the oil phase mixture with stirring.

[0059] Exemplarily, optionally, in some embodiments of the present application, the aqueous phase mixture is added dropwise to the oil phase mixture, comprising:

[0060] Add the polypeptide into water, stir and mix evenly to obtain a uniformly mixed aqueous phase mixture;

[0061] The phospholipids, oils and antioxidants are mixed, and heated and stirred to mix uniformly to obtain a uniformly mixed oil phase mixture;

[0062] Then, the uniformly stirred aqueous phase mixture is added dropwise into the uniformly mixed oil phase mixture, and stirred at room temperature until viscous reverse micelles are formed.

[0063] Further, in some embodiments of the present application, the aqueous phase mixture is added dropwise to the oil phase mixture, comprising:

[0064] In terms of mass percentage, 1%-3% of the water phase mixture is added dropwise into 97%-99% of the oil phase mixture and stirred.

[0065] For example, in some embodiments of the present application, the aqueous phase mixture is added dropwise to the oil phase mixture, comprising:

[0066] Measure by mass percentage, add 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3% or the aqueous phase mixture in the range between any two of the foregoing values ​​dropwise to 97%, 97.2%, 97.5%, 97.8%, 98%, 98.2%, 98.5%, 98.8%, 99% or the oil phase mixture in the range between any two of the foregoing values ​​and stir.

[0067] In the above technical solution, by mass percentage, 1%-3% of the aqueous phase mixture is added dropwise to the 97%-99% of the oil phase mixture and stirred. Within the above range, it is beneficial to obtain a viscous reverse micelle structure with moderate viscosity, which is beneficial to increase the retention of the polypeptide in the skin.

[0068] Further, in some embodiments of the present application, the oil includes at least one of isopropyl palmitate, isopropyl myristate, isopropyl laurate or isopropyl acetate. Exemplarily, in some embodiments of the present application, the oil is selected from any one of isopropyl palmitate, isopropyl myristate, isopropyl laurate or isopropyl acetate; or in some embodiments of the present application, the oil includes a mixture of isopropyl palmitate and isopropyl myristate, or in some embodiments of the present application, the oil includes a mixture of isopropyl laurate and isopropyl acetate; or in some embodiments of the present application, the oil includes a mixture of isopropyl palmitate, isopropyl myristate, isopropyl laurate and isopropyl acetate; each raw material in the above-mentioned mixtures can be mixed in any proportion.

[0069] Furthermore, in some embodiments of the present application, the antioxidant includes at least one of butylated hydroxyanisole, butylated hydroxytoluene, tocopheryl acetate, propyl gallate or tert-butylhydroquinone.

[0070] Illustratively, in some embodiments of the present application, the antioxidant is selected from: any one of butylated hydroxyanisole, butylated hydroxytoluene, tocopherol acetate, propyl gallate or tert-butylhydroquinone; or in some embodiments of the present application, the antioxidant includes: a mixture of butylated hydroxyanisole and butylated hydroxytoluene, or in some embodiments of the present application, the antioxidant includes: a mixture of butylated hydroxytoluene and tocopherol acetate; or in some embodiments of the present application, the antioxidant includes: a mixture of butylated hydroxytoluene, tocopherol acetate, propyl gallate, and tert-butylhydroquinone; the various raw materials in the above-mentioned mixtures can be mixed in any proportion.

[0071] Furthermore, in some embodiments of the present application, the polypeptide includes at least one of conopeptide, snake venom peptide or acetyl hexapeptide-8.

[0072] Illustratively, in some embodiments of the present application, the polypeptide is selected from: any one of conopeptide, snake venom peptide or acetyl hexapeptide-8; or in some embodiments of the present application, the above polypeptide is selected from: a mixture of conopeptide and snake venom peptide; or in some embodiments of the present application, the above polypeptide is selected from: a mixture of conopeptide, snake venom peptide and acetyl hexapeptide-8; the various raw materials in the above mixtures can be mixed in any proportion.

[0073] Furthermore, in some embodiments of the present application, the phospholipid includes lecithin, and the purity of the lecithin is 90% to 100%.

[0074] Illustratively, in some embodiments of the present application, the purity of lecithin is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% or a range between any two of the foregoing values.

[0075] In a second aspect, some embodiments of the present application provide an anti-aging cosmetic, which includes a polypeptide raw material; the polypeptide raw material forms a viscous reverse micelle structure.

[0076] Furthermore, in some embodiments of the present application, the polypeptide raw material includes, by mass percentage: 45%-78% oil; 20%-50% phospholipids; 1.0%-2.0% antioxidant; and 1.0%-3.0% water; 0.0001%-1.0% polypeptide.

[0077] Illustratively, in some embodiments of the present application, the polypeptide raw material includes, by mass percentage: 45%, 47%, 49.5%, 50%, 50.5%, 51%, 51.5%, 52%, 52.5%, 53%, 53.5%, 55%, 56%, 58%, 60%, 62%, 65%, 68%, 70%, 72%, 75%, 78% or fats in the range between any two of the foregoing values;

[0078] 20%, 22%, 24%, 26%, 28%, 30%, 35%, 40%, 45%, 48%, 50% or a range between any two of the foregoing phospholipids;

[0079] 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0% or a range between any two of the foregoing antioxidants;

[0080] 1.0%, 1.1%, 1.2%, 1.3%, 1.5%, 1.8%, 2%, 2.1%, 2.2%, 2.3%, 2.5%, 2.6%, 2.8%, 3% or a range between any two of the foregoing water; and

[0081] 0.0001%, 0.0005%, 0.001%, 0.005%, 0.01%, 0.05%, 0.1%, 0.15%, 0.5%, 0.8%, 1.0% or a range between any two of the foregoing values.

[0082] In the above technical scheme, the polypeptide raw materials include, by mass percentage: 45%-78% oil; 20% to 50% phospholipids; 1.0%-2.0% antioxidants; and 1.0%-3.0% water; 0.0001%-1.0% polypeptide; within this ratio range, polypeptide anti-aging cosmetics with longer retention in the skin can be obtained, which is beneficial to improving the real anti-aging effect of anti-aging cosmetics.

[0083] Furthermore, in some embodiments of the present application, the oil includes at least one of isopropyl palmitate, isopropyl myristate, isopropyl laurate or isopropyl acetate.

[0084] Furthermore, in some embodiments of the present application, the antioxidant includes at least one of butylated hydroxyanisole, butylated hydroxytoluene, tocopheryl acetate, propyl gallate or tert-butylhydroquinone.

[0085] Furthermore, in some embodiments of the present application, the polypeptide includes at least one of conopeptide, snake venom peptide or acetyl hexapeptide-8.

[0086] Furthermore, in some embodiments of the present application, the phospholipid includes lecithin, and the purity of the lecithin is 90% to 100%.

[0087] Illustratively, in some embodiments of the present application, the purity of the lecithin is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% or a range between any two of the foregoing values.

[0088] In other optional embodiments of the present application, the above-mentioned anti-aging cosmetics may also include other applicable cosmetic bases commonly used in the art, and the above-mentioned polypeptide raw materials are compounded with the cosmetic base to form anti-aging cosmetics.

[0089] Further optionally, in some embodiments of the present application, in the above-mentioned anti-aging cosmetics, the added amount of the aforementioned polypeptide raw material is 0.0001% to 1.0% by mass; illustratively, in some embodiments of the present application, in the above-mentioned anti-aging cosmetics, the added amount of the aforementioned polypeptide raw material is 0.0001%, 0.0005%, 0.001%, 0.002%, 0.003%, 0.01%, 0.02%, 0.03%, 0.05%, 0.1%, 0.2%, 0.5%, 0.8%, 1.0% or a range between any two of the aforementioned values.

[0090] Further optionally, in some embodiments of the present application, the above-mentioned cosmetic base may include moisturizers, emulsifiers, thickeners, etc. commonly used in the art.

[0091] The features and performance of the present application are further described in detail below in conjunction with the embodiments:

[0092] Examples and Comparative Examples

[0093] A polypeptide raw material is provided, and the proportions and compositions of various embodiments are shown in Tables 1 to 3;

[0094] Table 1

[0095]

[0096]

[0097] Table 2

[0098]

[0099] Table 3

[0100]

[0101]

[0102] Preparation process:

[0103] Weigh each raw material according to the composition ratio of each embodiment or comparative example in Table 1 to Table 3 above:

[0104] Each example was prepared according to the following preparation method:

[0105] S1, mixing phospholipids, oils and antioxidants, heating and stirring to form a uniform oil phase mixture;

[0106] S2, mixing and stirring the various raw materials of the aqueous phase to form a uniform aqueous phase mixture;

[0107] S3. Add the uniform aqueous phase mixture obtained in step S2 dropwise into the uniform oil phase mixture obtained in step S2, and stir at room temperature until viscous reverse micelles are formed.

[0108] Each comparative example was prepared according to the following preparation method:

[0109] S1. Mix and stir the various raw materials of the aqueous phase to form a uniform aqueous phase mixture.

[0110] Performance Testing

[0111] 1. In vitro transdermal test:

[0112] The samples prepared in the above-mentioned embodiments and comparative examples were respectively subjected to in vitro pig skin permeation experiments using a vertical Franz diffusion cell method:

[0113] The suckling pig skin was fixed in the receiving chamber and the supply chamber, and 0.5 g of the reverse micelle carrier sample of each embodiment and the polypeptide aqueous solution sample of Comparative Examples 1-3 were taken into the supply chamber, and a PBS buffer solution with a pH of 7.4 was used as the receiving solution, and stirred and diffused at 32°C. After 24 hours, the skin was removed, washed and cut into pieces, and an appropriate amount of PBS buffer solution was added. After shaking for half an hour, the supernatant was taken for HPLC detection and analysis, and the intradermal retention per unit area of ​​the specific component was calculated. The experimental results are shown in Table 4.

[0114] Table 4

[0115]

[0116]

[0117] From the test results in Table 4 above, it can be seen that:

[0118] The results of intradermal retention showed that compared with the polypeptide aqueous solutions of each comparative example, the reverse micelle carriers provided in each embodiment for carrying polypeptides increased the intradermal retention of the polypeptides to varying degrees, especially the reverse micelle carriers with a ratio of 69.3% oil phase, 28.5% phospholipids, 1% antioxidants and 1.5% aqueous phase, wherein the aqueous phase includes 90% water and 10% polypeptides, which can increase the intradermal retention of polypeptides by 71%-219%.

[0119] The viscosity was tested using the test method shown above. The viscosity results in Table 4 show that compared with the polypeptide aqueous solutions of each comparative example, the reverse micelle carriers provided in each embodiment have greatly improved viscosity to varying degrees due to the formation of a reverse micelle structure, wherein the viscosity of the reverse micelle carrier increases with the increase of the phospholipid content. However, the intradermal retention of the polypeptide does not increase with the increase of viscosity, but decreases instead. This is because excessively high viscosity of the reverse micelle carrier will result in the release of the encapsulated polypeptide being hindered, while an appropriate viscosity (25000Pa·s-35000Pa·s) has both a reverse micelle structure and a certain fluidity, which can better improve the intradermal retention of the polypeptide.

[0120] Applying this reverse micelle carrier to carry peptides in anti-aging cosmetics can greatly increase the intradermal retention of peptides, maximize their efficacy, and thus improve the anti-aging effect of cosmetics.

[0121] 2. Microstructure characterization

[0122] The microstructures of the samples of Example 2, Example 7, and Example 12 were observed using a transmission electron microscope respectively:

[0123] 10 μl of each sample was respectively added to the copper grid for precipitation for 1 min, and the floating liquid was removed by filter paper; 10 μl of uranyl acetate staining solution was added to the copper grid for precipitation for 1 min, and the floating liquid was removed by filter paper; the mixture was dried at room temperature for several minutes; the electron microscope was used for imaging at 80 kV-120 kV, and the images were collected for analysis.

[0124] Transmission electron microscopy results are shown in the instruction manual. Figure 1 -Attached Figure 3 .

[0125] From the instruction manual Figure 1 -Attached Figure 3 From the transmission electron microscopy images we can see that:

[0126] The samples of each embodiment all present a reverse micelle structure; and each reverse micelle structure is nanoscale circular, and the pore size of the reverse micelle structure after loading cono peptide, snake venom peptide and acetyl hexapeptide-8 is about 100nm-200nm. This structure with a nanoscale pore size is more conducive to carrying polypeptides to penetrate into the skin and improving the retention of polypeptides in the skin. This is because the gap between the lipid bilayer of the normal stratum corneum is about 10nm-20nm. When the size of the reverse micelle carrier is about 100nm-200nm, its size is relatively moderate. On the one hand, it is larger than the gap between the intercellular lipid bilayer, and it will not easily pass through the normal lipid channel, thereby avoiding passing through the stratum corneum too quickly and not being able to play an effective role; on the other hand, this size is not too large, so that it can promote polypeptide penetration by adhering to / penetrating the skin, increasing skin hydration, relaxing the skin structure and changing polarity, and exchanging lipids with intercellular lipids.

[0127] The above description is only the preferred embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the protection scope of the present application.

Claims

1. A method for increasing the intradermal retention of a polypeptide in a cosmetic, characterized in that: include: mixing the polypeptide with water to prepare an aqueous phase mixture; The phospholipids, oils and antioxidants are mixed to prepare an oil phase mixture; The aqueous phase mixture is added dropwise to the oil phase mixture to form a viscous reverse micelle structure.

2. The method for increasing the intradermal retention of polypeptides in cosmetics according to claim 1, characterized in that: The method of mixing the polypeptide with water to obtain an aqueous phase mixture comprises: In the aqueous phase mixture, the polypeptide and the water are mixed in the ratio of (0.01% to 70%): (30% to 99.99%) by mass percentage.

3. The method for increasing the intradermal retention of polypeptides in cosmetics according to claim 1, characterized in that: The method of mixing phospholipids, oils and antioxidants to prepare an oil phase mixture comprises: In terms of mass percentage, the phospholipid, the oil and the antioxidant are mixed in the ratio of (20% to 50%): (45% to 78%): (1.0% to 2.0%).

4. The method for increasing the intradermal retention of polypeptides in cosmetics according to claim 1, characterized in that: The step of adding the aqueous phase mixture dropwise to the oil phase mixture comprises: The uniform aqueous phase mixture was added dropwise into the oil phase mixture with stirring.

5. The method for increasing the intradermal retention of polypeptides in cosmetics according to claim 1, characterized in that: The step of adding the aqueous phase mixture dropwise to the oil phase mixture comprises: In the water phase mixture, 1% to 3% of the water phase mixture is added dropwise into 97% to 99% of the oil phase mixture by mass percentage, and stirred.

6. The method for increasing the intradermal retention of a polypeptide in a cosmetic according to any one of claims 1 to 5, characterized in that: The oil comprises at least one of isopropyl palmitate, isopropyl myristate or isopropyl laurate; The antioxidant includes tocopherol acetate.

7. The method for increasing the intradermal retention of a polypeptide in a cosmetic according to any one of claims 1 to 5, characterized in that: The polypeptide comprises at least one of conopeptide, snake venom peptide or acetyl hexapeptide-8.

8. The method for increasing the intradermal retention of a polypeptide in a cosmetic according to any one of claims 1 to 5, characterized in that: The phospholipids include lecithin, and the purity of the lecithin is 90% to 100%.

9. An anti-aging cosmetic, characterized in that: The anti-aging cosmetics include polypeptide raw materials; The polypeptide raw material forms a viscous reverse micelle structure; Optionally, the pore size of the reverse micelle structure is 100nm-200nm; Optionally, the viscosity of the reverse micelle structure is 25000 Pa·s-35000 Pa·s.

10. The anti-aging cosmetic according to claim 9, characterized in that: According to the percentage by mass, the polypeptide raw material comprises: 45%-78% oil; 20%-50% phospholipid; 1.0%-2.0% antioxidant; 1.0%-3.0% water; and 0.0001%-1.0% polypeptide; Optionally, the oil comprises: at least one of isopropyl palmitate, isopropyl myristate or isopropyl laurate; Optionally, the antioxidant includes: tocopherol acetate; Optionally, the polypeptide comprises at least one of conopeptide, snake venom peptide or acetyl hexapeptide-8; Optionally, the phospholipid includes lecithin, and the purity of the lecithin is 90% to 100%.

Images